A recent industry analysis finds that the global amyotrophic lateral sclerosis (ALS) therapeutics landscape, valued at about USD 812 million in 2024, is expected to grow to around USD 1,964 million by 2035, with an annual growth rate of about 11.5 percent through the forecast period, according to the research. The analysis covers a range of treatment types including chemotherapy‑based drugs, antisense oligonucleotide therapies, gene therapy, gene‑silencing therapies and others, tracking developments across therapeutic classes and routes of administration.
Key companies featured in the analysis include Alnylam Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Biogen Inc., Ionis Pharmaceuticals, Amylyx Pharmaceuticals, Cytokinetics, BrainStorm Cell Therapeutics, Annexon Biosciences, AB Science, QurAlis Corporation, MediciNova Inc., Takeda Pharmaceutical Company, Sanofi, Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics, Biohaven Pharmaceutical, Alchemab Therapeutics, Celosia Therapeutics, Neuvivo Inc., among others.
The analysis highlights increasing emphasis on disease‑modifying treatment approaches and neuroprotective strategies that could transform care for ALS, a progressive neurodegenerative condition with limited curative options. Antisense oligonucleotides, gene‑targeted modalities and biologics are cited as innovation areas supporting growth, as stakeholders seek therapies that go beyond symptomatic management.
Despite the projected expansion, challenges such as complex clinical development and the rarity of ALS remain obstacles. Collaboration across specialty biopharma firms, research centres and regulatory agencies is seen as a driver of advancement in the ALS therapeutics field.
